# Eloralintide Dosing Guide: Phase 2 Doses, Titration, and Weekly Protocol
> Note: PeptIQ is not a medical provider. Eloralintide is investigational. The doses below come from published clinical trial designs and should not be treated as a consumer protocol, research-peptide recipe, or medical recommendation.
"Eloralintide dosage" is already becoming a high-intent search — the same pattern that made retatrutide dosing and MOTS-c dosing pages win traffic. The useful answer is not a forum guess. It is the Phase 2 dose map: what Lilly actually tested, how titration arms worked, and what weight-loss signal showed up at each level.
Quick Answer: How Was Eloralintide Dosed?
In the pivotal Phase 2 obesity trial (NCT06230523), eloralintide was given as a once-weekly subcutaneous injection for 48 weeks, with these arms:
| Arm | Weekly dose approach |
|---|---|
| Low fixed | 1 mg once weekly |
| Low–mid fixed | 3 mg once weekly |
| Mid fixed | 6 mg once weekly |
| High fixed | 9 mg once weekly |
| Escalation A | 6 mg → 9 mg |
| Escalation B | 3 mg → 6 mg → 9 mg |
| Control | Placebo once weekly |
That is the core dosing vocabulary for eloralintide in 2026 coverage.
Why Titration Arms Exist
Amylin agonists, like GLP-1s, can cause gastrointestinal side effects — nausea, early fullness, constipation — especially during escalation. Fixed high doses answer "how much weight loss is possible?" Escalation arms answer "can you reach a high maintenance dose with better tolerability?"
Lilly tested both. That matters for how you read the results:
- Fixed 9 mg shows the top-end efficacy signal
- 3→6→9 mg and 6→9 mg show whether a slower climb preserves response
In the efficacy estimand at 48 weeks, mean weight reduction ranged roughly ~9% (1 mg) to ~20% (9 mg and 6–9 mg escalation), with placebo near 0%. Mid doses (3–6 mg) landed in between. Exact confidence intervals are in the Lancet paper; the directional lesson is clear: dose matters, and higher once-weekly exposure drove larger mean loss.
How to Read an Eloralintide Dose Table (Without Overclaiming)
When people ask for an "eloralintide dosing protocol," they usually want one of three things:
- Trial literacy — what Phase 2 / Phase 3 actually used
- Comparison — how it stacks against cagrilintide or GLP-1 titration
- Tracking template — what to log if a clinician ever involves an amylin agonist
Only #1 and #3 are appropriate for most readers today. Eloralintide is not an approved consumer therapy, and research-market products are not clinical-trial product.
Phase 2 efficacy snapshot (educational)
| Weekly regimen | Approximate mean weight change at ~48 weeks (efficacy estimand) |
|---|---|
| 1 mg | ~−9% |
| 3 mg | ~−12% |
| 6 mg | ~−18% |
| 9 mg | ~−20% |
| 6→9 mg escalation | ~−20% |
| 3→6→9 mg escalation | ~−16% |
| Placebo | ~0% |
Numbers are rounded from the public Phase 2 readout for clarity. Always prefer the peer-reviewed table for citations.
Frequency and Timing
- Frequency: once weekly in studied protocols
- Route: subcutaneous
- Missed-dose logic: follow clinical-trial / label guidance if a product is ever approved; do not invent catch-up rules from forum posts
- Food timing: amylin agonism affects satiety and gastric emptying — many people feel strongest meal-size effects around the injection window; log meal tolerance on dose day vs mid-week
Unlike MOTS-c (often timed fasted / pre-workout), eloralintide is a weekly metabolic medicine pattern closer to semaglutide or tirzepatide calendars.
Eloralintide vs Other Weekly Metabolic Doses (Context Only)
| Compound | Typical studied weekly range (obesity programs) | Pathway |
|---|---|---|
| Eloralintide | 1–9 mg (Phase 2) | Selective amylin |
| Cagrilintide (in CagriSema) | 2.4 mg with semaglutide 2.4 mg | Amylin + GLP-1 |
| Survodutide | up to 3.6–6.0 mg (Phase 3) | Glucagon + GLP-1 |
| Retatrutide | multi-mg titration in TRIUMPH | GLP-1 + GIP + glucagon |
These are not interchangeable milligram-for-milligram. Different receptors, different exposure–response curves.
